US Markets
JNJ

J&J says U.S. FDA agrees to extend shelf life of its COVID-19 vaccine

Credit: REUTERS/Jon Nazca

The U.S. Food & Drug Administration extended the shelf life for Johnson & Johnson's single-shot COVID-19 vaccine to six months from four-and-a-half months, the company said late Wednesday.

Adds J&J statement, changes source in lede to J&J

July 28 (Reuters) - The U.S. Food & Drug Administration extended the shelf life for Johnson & Johnson's JNJ.N single-shot COVID-19 vaccine to six months from four-and-a-half months, the company said late Wednesday.

The FDA's decision is based on data from ongoing studies, which showed the vaccine is stable at six months when refrigerated at 2 to 8 degrees Celsius (36–46 degrees Fahrenheit), the drugmaker said. (https://bit.ly/3ypgpTT)

In a letter to the company, the FDA said it had completed the review of data provided by J&J, and based on the information submitted, it concurs with the extension. (https://bit.ly/3zRuTMB)

The agency also said the extension was applicable to batches that might have expired prior to the issuance of the letter provided they were stored at the recommended temperature.

(Reporting by Aakriti Bhalla in Bengaluru; Editing by Shinjini Ganguli and Subhranshu Sahu)

((Aakriti.Bhalla@thomsonreuters.com;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

JNJ

Latest Markets Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More